MicroRNA inhibition using antimiRs in acute human brain tissue sections

Area of Science:

• Neuroscience
• Molecular Biology
• Pharmacology

Background:

• Pharmacoresistant epilepsy presents a significant clinical challenge.
• MicroRNA (miRNA) inhibition is a promising preclinical therapeutic strategy.
• Current antimiR testing relies on animal models, limiting direct human relevance.

Purpose of the Study:

• To establish a novel platform for testing antimiR efficacy in human brain tissue.
• To evaluate the effectiveness of an antimiR targeting microRNA-134 (ant-134) in human neocortical sections.
• To assess the safety and specificity of ant-134 in a human ex vivo model.

Main Methods:

• Human neocortical specimens from epilepsy surgery were used.
• Tissue sections were incubated with ant-134 or control antimiR in artificial cerebrospinal fluid (ACSF).
• RNA integrity was assessed, and miR-134 levels were quantified using RT-qPCR.

Main Results:

• Human brain tissue maintained good RNA integrity after transport in ACSF.
• Ant-134 demonstrated dose-dependent knockdown of miR-134, achieving up to 90% reduction.
• No off-target effects were observed on other selected miRNAs at tested doses.

Conclusions:

• This study provides the first evidence of ant-134 activity in live human brain tissue.
• The developed platform enables preclinical testing of antimiRs and other antisense oligonucleotides in human tissue.
• Findings support the further preclinical development of miR-134 targeted therapies for pharmacoresistant epilepsy.